Cambridge, United States
CAMP4 Therapeutics is a forward-thinking company in the biopharma and biotechnology sectors, founded in 2016 and headquartered in the United States. The company is on the cutting edge of developing ASO-based, RNA-targeting therapeutics with the aim of restoring healthy protein levels. Their approach focuses on programmable therapeutics to upregulate gene expression, potentially offering treatments for a wide range of diseases.
With their proprietary platform, CAMP4 Therapeutics leverages a deep understanding of regulatory RNA and gene expression. This innovative methodology could unlock treatments for hundreds of diseases, impacting millions of patients globally.
Significantly, the company secured a substantial $100.00M through a Private Placement Non VC investment on 01 September 2025, reflecting strong investor confidence. This influx of capital positions CAMP4 Therapeutics well to advance its therapeutic pipeline and drive future growth.
